Status:
WITHDRAWN
Efficacy of Fractional Er:YAG Laser in Lupus Erythematosus Scars
Lead Sponsor:
Insel Gruppe AG, University Hospital Bern
Conditions:
Lupus Erythematosus, Cutaneous
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Cutaneous Lupus erythematosus (CLE) is a chronic autoimmune connective tissue disease with a prevalence of 14.6 - 73.2/100,000, predominantly in women in mid adulthood. Cutaneous lesions occur in abou...
Eligibility Criteria
Inclusion
- Informed consent
- Skin type I-IV
- Presence of \>1 scar due to CLE at one localisation
- Stable disease (without or with permanent therapy \>3months)
Exclusion
- History of adverse events related to ablative fractional laser therapy
- Ablative resurfacing within the last 6 months on the scar
- Pregnant or breast feeding women
- Intake of isotretinoin in the last 6 month
- Intention to become pregnant during the course of the study
- Any scar treatment in the last 3 month before inclusion
Key Trial Info
Start Date :
June 1 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2022
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT04707924
Start Date
June 1 2021
End Date
December 1 2022
Last Update
December 6 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of dermatology, University Hospital Inselspital, Bern
Bern, Switzerland, 3010